May 28, 2025 6:30am EDT Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
May 08, 2025 6:30am EDT Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Mar 31, 2025 8:30am EDT Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Feb 13, 2025 6:30am EST Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Feb 06, 2025 8:30am EST Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
Feb 04, 2025 8:30am EST Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
